Advertisement
Australia markets closed
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • AUD/USD

    0.6519
    -0.0016 (-0.25%)
     
  • OIL

    82.33
    +0.98 (+1.20%)
     
  • GOLD

    2,229.90
    +17.20 (+0.78%)
     
  • Bitcoin AUD

    108,817.33
    +1,329.85 (+1.24%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • AUD/EUR

    0.6025
    -0.0005 (-0.09%)
     
  • AUD/NZD

    1.0892
    +0.0012 (+0.11%)
     
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NASDAQ

    18,295.39
    +14.54 (+0.08%)
     
  • FTSE

    7,963.34
    +31.36 (+0.40%)
     
  • Dow Jones

    39,776.10
    +16.02 (+0.04%)
     
  • DAX

    18,499.50
    +22.41 (+0.12%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     

Company News For Sep 4, 2019

  • Conn's, Inc.’s CONN shares rose 18.3% after the company reported second quarter fiscal 2020 earnings per share of $0.62, surpassing the Zacks Consensus Estimate of $0.51

  • The Medicines Company’s MDCO shares gained 10.4% after the company reported positive results from its ORION-11 trial at ESC Congress 2019.

  • Shares of Emergent BioSolutions Inc. EBS surged 14.5% after the company received a 10-year HHS contract to provide ACAM2000 smallpox vaccines to the U.S. Strategic National Stockpile

  • Shares of Royal Caribbean Cruises Ltd. RCL fell 1.4% afterthe reorts surfaced that the company could suffer losses of up to $0.05 a share in the current quarter due to the impact of Hurricane Dorian


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Royal Caribbean Cruises Ltd. (RCL) : Free Stock Analysis Report
 
Emergent Biosolutions Inc. (EBS) : Free Stock Analysis Report
 
The Medicines Company (MDCO) : Free Stock Analysis Report
 
Conn's, Inc. (CONN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research